Studying GATA3, FOXA1, and ELF5 transcription factors in the evaluation of prognosis in luminal breast cancer patients
Open Access
- 7 January 2021
- journal article
- research article
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 19 (4) , 30-37-37
Abstract
Исследование факторов транскрипции GATA3, FOXA1, ELF5 в оценке прогноза у больных люминальным раком молочной железыKeywords
This publication has 18 references indexed in Scilit:
- GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent diseaseCancer Letters, 2016
- Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysisThe Breast, 2016
- Clinicopathological significance of forkhead box protein A1 in breast cancer: A meta-analysisExperimental and Therapeutic Medicine, 2016
- GATA3 Expression in Advanced Breast Cancer: Prognostic Value and Organ-Specific RelapseAmerican Journal of Clinical Pathology, 2015
- Breast Cancer Subtypes Predispose the Site of Distant MetastasesAmerican Journal of Clinical Pathology, 2015
- Infrequent Loss of Luminal Differentiation in Ductal Breast Cancer MetastasisPLOS ONE, 2013
- ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast CancerPLOS Biology, 2012
- Elf5 inhibits the epithelial–mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2Nature Cell Biology, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The Ets transcription factor Elf5 specifies mammary alveolar cell fateGenes & Development, 2008